| Literature DB >> 35118298 |
Sara Ricciardi1, Federico Davini2, Gaetano Romano2, Carmelina Cristina Zirafa2, Franca Melfi3.
Abstract
BACKGROUND: Robotic-assisted thoracic surgery has been shown as a safe and feasible surgical procedure to treat a broad range of thoracic malignancies with a shorten hospital stay, a quicker return to normal daily activities and superior quality of life compared to open approach. Nonetheless, its utilization has predominantly been restricted to the average surgical intervention. In the latest years, given the technological improvements and the advanced skills of the "robotic" surgeons, this approach has been applied to more complex and challenging procedures (e.g., advanced stages/ after neoadjuvant therapies). The aim of this study is to show the results and the advantages of redo thoracic procedures performed with a robot-assisted approach.Entities:
Keywords: Robotic thoracic surgery; lung; mediastinum; minimally invasive; non-small cell lung cancer (NSCLC); redo surgery
Year: 2020 PMID: 35118298 PMCID: PMC8794424 DOI: 10.21037/med-20-47
Source DB: PubMed Journal: Mediastinum ISSN: 2522-6711
Patients’ characteristics and previous treatment
| Patient | Age | Sex | Comorbidities | Previous treatment | Site | Complication | Histopathological result | Approach |
|---|---|---|---|---|---|---|---|---|
| 1 | 76 | M | COPD, hypertension, diabetes | Radiotherapy | RUL | Unknown | NSCLC | RT |
| 2 | 49 | F | None | Ganglioneuroma removal | Posterior mediastinal space | Prolonged air leak Pleural effusion | Ganglioneuroma | Thoracotomy |
| 3 | 73 | M | Hypertension | Lobectomy | RUL + wedge resection ML | Prolonged air leak | NSCLC pT1cN0 (squamous cell) | Thoracotomy |
| 4 | 57 | M | None | Thymoma removal en-bloc with right phrenic nerve and part of lung (wedge of RLL) | Anterior mediastinal space | Blood loss (1,100 mL) | Thymoma B2, stage IV | Sternotomy |
| 5 | 76 | F | Myasthenia gravis | Inferior bilobectomy | ML + RLL | Unknown | Abscess | Thoracotomy |
| 6 | 72 | F | hypertension, hypothyroidism, cerebral aneurysm | Lobectomy | LUL | None | NSCLC pT3N0 (adenocarcinoma) | Robot |
| 7 | 84 | M | Atrial fibrillation, hypertension | SBRT | ML | Unknown | NSCLC | RT |
| 8 | 58 | M | Hypertension, ischemic heart disease | Chemo-radiation therapy | LUL | Unknown | NSCLC | CHT + RT |
| 9 | 74 | F | Previous pancreatic neoplasm (2011) | Anterior segment RUL | RUL | None | NSCLC pT1aN0 (adenocarcinoma) | Thoracotomy |
COPD, chronic obstructive pulmonary disease; RUL, right upper lobe; NSCLC, non-small cell lung cancer; RT, radiotherapy; RLL, right lower lobe; ML, middle lobe; LUL, left upper lobe; SBRT, stereotactic body radiation therapy; CHT, chemotherapy.
Figure 1Right upper lobe after radiation therapy with curative intent.
Figure 2Left upper lobe post concurrent chemo-radiation therapy with curative intent.
Intraoperative results
| Patient | Distance from previous treatment (months) | Site | PFR | Operation | Duration of surgery (minutes) | Challenging | Blood loss (mL) | Complication |
|---|---|---|---|---|---|---|---|---|
| 1 | 100 | RUL | FEV1 1.6, FVC 3.2, FEV1/FVC 50% | Lobectomy | 270 | Sclerotic nodes, fibrotic hilar tissue | 30 | None |
| 2 | 444 | Posterior mediastinal space | FEV1 3.11, FVC 4.43, FEV1/FVC 88% | Ganglioneuroma removal + wedge resection of RUL | 245 | Adhesions, scarring tissue | 50 | Prolonged air leak |
| 3 | 10 | ML | FEV1 1.86, FVC 3.41, FEV1/FVC 55% | Lobectomy (completion) | 615 | Adhesions, hilar structures rearrangement | 325 | None |
| 4 | 7 | Parietal pleura | – | Pleurectomy + HITHOC | 455 (of which 120 of HITHOC) | Adhesions | 300 | None |
| 5 | 173 | Anterior mediastinal space | – | Thymoma removal | 65 | Adhesions | 30 | None |
| 6 | 13 | LLL | FEV1 1.49, FVC 2.17, FEV1/FVC 69% | Pneumonectomy (completion) | 360 | Adhesions, hilar structures rearrangement, mediastinal tissue rearrangement | 100 | None |
| 7 | 10 | ML | FEV1 1.96, FVC 2.34, FEV1/FVC 84% | Lobectomy | 135 | Sclerotic tissue | 100 | None |
| 8 | 12 | LUL | FEV1 2.95, FVC 3.94, FEV1/FVC 75% | Lobectomy | 280 | Adhesion, sclerotic tissue | 50 | None |
| 9 | 96 | RUL | FEV1 1.28, FVC 2.16, FEV1/FVC 59% | Lobectomy | 300 | Adhesion, hilar structures rearrangement | 100 | None |
RUL, right upper lobe; ML, middle lobe; HITHOC, hyperthermic intrathoracic chemotherapy; LLL, left lower lobe; LUL, left upper lobe; FEV1, forced expiratory volume in the 1st second; FVC, forced vital capacity.
Figure 3Ganglioneuroma relapse after resection 37 years before.
Figure 4Thymoma post inferior bilobectomy.
Postoperative results
| Patient | Histological | Stage | Length of stay (days) | Number of chest tube | Chest tube stay (days) | Adjuvant therapy |
|---|---|---|---|---|---|---|
| 1 | Squamous cell carcinoma | T2aN0 | 4 | 2 | 4 | None |
| 2 | Ganglioneuroma | Ki-67 =1% | 6 | 1 | 5 | None |
| 3 | Squamous cell carcinoma | Relapse | 5 | 2 | 4 | None |
| 4 | Thymoma B1 | M1 | 6 | 2 | 5 | Chemotherapy |
| 5 | Thymoma AB/B1 | T1N0 | 4 | 1 | 2 | None |
| 6 | Adenocarcinoma | T2aN0 | 10 | 1 | 2 | None |
| 7 | Adenocarcinoma | CRC metastasis | 5 | 1 | 2 | Chemotherapy |
| 8 | Adenocarcinoma | T2bN1 | 4 | 1 | 2 | Chemotherapy |
| 9 | Adenocarcinoma | T1bN0 | 5 | 1 | 2 | None |
Video 1Pleural adhesion, robotic adhesiolysis.
Video 2Tissue rearrangement, sclerotic lymph node.